866-997-4948(US-Canada Toll Free)

Global Hepatocellular Carcinoma Drugs Market 2017-2021

Published By :

Technavio

Published Date : Sep 2017

Category :

Oncology

No. of Pages : 86 Pages

About Hepatocellular Carcinoma Drugs

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

Technavios analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Hepatocellular Carcinoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Bayer
Eli Lilly
Johnson and Johnson
Pfizer

Other prominent vendors
Bristol-Myers Squibb
Celgene
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Novartis
Salix Pharmaceuticals
Transgene

Market driver
Growing cases of hepatitis B and C infections
For a full, detailed list, view our report

Market challenge
Stringent government regulations and trial failure in the late stage of drug development
For a full, detailed list, view our report

Market trend
Increase in R&D activities for liver cirrhosis medication
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
Market size and forecast
Five forces analysis
PART 06: Pipeline landscape
PART 07: Market segmentation by therapy
Chemotherapy
Brachytherapy
Ablation therapy
PART 08: Geographical segmentation
HCC drugs market in Americas
HCC drugs market in EMEA
HCC drugs market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
Market drivers
Market challenges
PART 11: Market trends
Increase in R&D activities for liver cirrhosis medication
Rise in awareness
PART 12: Vendor landscape
Competitive scenario
PART 13: Key vendor analysis
Bayer
Eli Lilly
Johnson and Johnson
Pfizer
Other prominent vendors
PART 14: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Functions of liver
Exhibit 02: Causes of HCC
Exhibit 03: Global HCC drugs market
Exhibit 04: Global HCC drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global HCC drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline based on vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global HCC drugs market segmentation based on therapies
Exhibit 10: Global HCC drugs market share as per therapies 2016 and 2021
Exhibit 11: Major types of chemotherapy
Exhibit 12: Global HCC chemotherapy drugs market 2016-2021 ($ millions)
Exhibit 13: NEXAVAR: Drug overview
Exhibit 14: STIVARGA: Drug overview
Exhibit 15: Global HCC brachytherapy drugs market 2016-2021 ($ millions)
Exhibit 16: Global HCC ablation therapy market 2016-2021 ($ millions)
Exhibit 17: Global HCC drugs market share by geography 2016 and 2021
Exhibit 18: Global HCC drugs market revenues by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: HCC drugs market in Americas 2016-2021 ($ millions)
Exhibit 21: Liver cancer scenario in the US 2016
Exhibit 22: Market scenario in EMEA
Exhibit 23: HCC drugs market in EMEA 2016-2021 ($ millions)
Exhibit 24: Top five countries with highest incidence of liver cancer
Exhibit 25: Market scenario in APAC
Exhibit 26: HCC drugs market in APAC 2016-2021 ($ millions)
Exhibit 27: Proportions of HBV and HCV-related HCC in APAC
Exhibit 28: Hepatitis C scenario 2016
Exhibit 29: Hepatitis B scenario 2016
Exhibit 30: Lifestyle disease effect on liver
Exhibit 31: Global liver transplants scenario 2014
Exhibit 32: Percentage distribution of transplants by organ in the US 1988-2016
Exhibit 33: Effects of chemotherapy drugs on human body
Exhibit 34: Competitive structure analysis of global HCC drugs market 2016
Exhibit 35: Strategic success factors of companies in global HCC drugs market
Exhibit 36: Bayer: Key highlights
Exhibit 37: Bayer: Strength assessment
Exhibit 38: Bayer: Strategy assessment
Exhibit 39: Bayer: Opportunity assessment
Exhibit 40: Eli Lilly: Key highlights
Exhibit 41: Eli Lilly: Strength assessment
Exhibit 42: Eli Lilly: Strategy assessment
Exhibit 43: Eli Lilly: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Pfizer: Key highlights
Exhibit 49: Pfizer: Strength assessment
Exhibit 50: Pfizer: Strategy assessment
Exhibit 51: Pfizer: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *